Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Effect of Acupuncture Plus Governor Vessel Moxibustion Combined With Letrozole on Live Birth in Anovulatory Infertile Women With Spleen-kidney Yang Deficiency PCOS
- Conditions
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Qiu-ping Lin
- Target Recruit Count
- 90
- Registration Number
- NCT04987632
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 1100
- Registration Number
- NCT04985266
- Locations
- 🇬🇧
Barnet Hospital, London, Barnet, United Kingdom
🇬🇧Royal Sussex Hospital, Brighton, United Kingdom
🇬🇧Velindre Cancer Centre, Cardiff, United Kingdom
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
- Conditions
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT04964934
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 70
- Registration Number
- NCT04942899
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 176
- Registration Number
- NCT04931342
- Locations
- 🇫🇷
CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France
🇫🇷Institut Bergonie; Oncologie, Bordeaux, France
🇫🇷Centre Francois Baclesse; Oncologie, Caen, France
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT04872608
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Haihe Biopharma Co., Ltd.
- Target Recruit Count
- 228
- Registration Number
- NCT04856371
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 1000
- Registration Number
- NCT04852081
- Locations
- 🇷🇺
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- First Hospital of China Medical University
- Target Recruit Count
- 1354
- Registration Number
- NCT04666805
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Registration Number
- NCT04630210
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.